Benzene and Acute Myeloid Leukemia: Evidence of Causation

From General Health Awareness to Specific Risk

The legacy of general health and science information has long served as a foundation for public understanding of environmental risks, emphasizing broad awareness of chemical hazards and their potential to affect well-being. Within this context, benzene has been recognized as a substance of concern, particularly in relation to its association with blood disorders. Historically, discussions have centered on community-level exposures, such as those from vehicle emissions or industrial pollution, framing the risk in terms of ambient environmental quality. This heritage provides a baseline for recognizing benzene as a hazardous agent, but it often lacks specificity regarding the intensity and duration of exposure that may elevate risk. As attention shifts from general population health to more focused scenarios, the occupational setting emerges as a critical area of concern. Workers in industries such as chemical manufacturing, petroleum refining, and rubber production may encounter benzene at concentrations far exceeding those found in the general environment.

Bridging to Occupational and Environmental Evidence

This transition from a broad health context to an occupational exposure concern highlights the need to examine how sustained, higher-level contact with benzene in the workplace may influence disease risk. The following discussion will explore the evidence linking occupational benzene exposure to acute myeloid leukemia, drawing on epidemiological studies that investigate this relationship. Benzene is a recognized human carcinogen, and a substantial body of epidemiological and mechanistic evidence links occupational and environmental exposure to an increased risk of acute myeloid leukemia (AML). Studies consistently demonstrate that benzene exposure is associated with AML, with the relationship considered causal for occupational exposures.

Epidemiological Evidence of Benzene and AML Risk

Occupational exposure to benzene at levels of 10 parts per million (ppm) or more has been associated with an increased risk of developing AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). This association is supported by large cohort studies. For example, an analysis of the Swiss National Cohort found that occupational benzene exposure is associated with elevated mortality risks for AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). The same study also reported elevated risks for other lymphohaematopoietic cancers, including diffuse large B-cell lymphoma and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). The causal relationship between occupational benzene exposure and AML has been established in previous research (https://pubmed.ncbi.nlm.nih.gov/38727681/). Environmental exposure to benzene also increases AML risk. A meta-analysis of 25 studies found that benzene exposure was associated with an increased risk of childhood acute myeloid leukemia, with an odds ratio of 1.22 (95% confidence interval: 1.02-1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). This finding indicates that even low-level ambient benzene exposure can elevate AML risk in susceptible populations such as children.

Mechanistic Pathways Linking Benzene to AML

The mode of action (MOA) for benzene-induced AML is understood to involve multiple key events. Benzene is a myelotoxin, meaning it is toxic to bone marrow, and it is able to augment the risk for the onset of acute myeloid leukemia, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The development of AML following benzene exposure is anticipated to include earlier key events observable as hematotoxicity and genetic toxicity in the peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would prevent the apical adverse outcomes of morbidity and mortality caused by myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Multiple mechanisms have been identified for benzene's initiation of hematological tumors. These include a genotoxic effect, action on oxidative stress and inflammation, and the provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Additionally, epigenetic effects, such as altered gene expression, are becoming recognized as important contributors to benzene's carcinogenic ability (https://pubmed.ncbi.nlm.nih.gov/34069279/). Genetic alterations alone are insufficient to fully explain the onset of hematologic malignancies, suggesting that epigenetic changes play a significant role (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Timeline and Causation Considerations

The latency period between benzene exposure and the development of AML can vary. Occupational studies have focused on exposures at levels of 10 ppm or more, with increased AML risk observed in workers with chronic exposure (https://pubmed.ncbi.nlm.nih.gov/33429013/). The Swiss National Cohort study assessed occupational exposure by applying a quantitative benzene job-exposure matrix to census-reported occupations, linking exposure to mortality from AML over the follow-up period (https://pubmed.ncbi.nlm.nih.gov/38727681/). This suggests that harm can be documented years or decades after exposure, consistent with the natural history of AML development. For patients with AML who have a history of benzene exposure, causation considerations include the level and duration of exposure, the latency period, and the presence of other risk factors. The established causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/) supports the attribution of disease to exposure in appropriate cases. The mode of action framework, which includes hematotoxicity and genetic toxicity as early key events, provides a biological basis for causation (https://pubmed.ncbi.nlm.nih.gov/33429013/). However, individual risk assessment must account for the multifactorial nature of AML, as benzene is one of several risk elements for hematological neoplasms (https://pubmed.ncbi.nlm.nih.gov/34069279/). The evidence indicates that benzene is a well-established cause of AML, with warnings and regulations in place in many jurisdictions. However, the continued occurrence of occupational and environmental exposures suggests that warnings may not be fully adequate in all settings. The identification of key events in the mode of action could inform more targeted prevention strategies (https://pubmed.ncbi.nlm.nih.gov/33429013/). The association between benzene and childhood AML at low exposure levels (https://pubmed.ncbi.nlm.nih.gov/41485753/) underscores the need for comprehensive public health warnings and exposure reduction measures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene to acute myeloid leukemia?

Epidemiological studies consistently show that occupational exposure to benzene at levels of 10 ppm or more increases AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The Swiss National Cohort study found elevated AML mortality with occupational exposure (https://pubmed.ncbi.nlm.nih.gov/38727681/). Environmental exposure also raises risk, with a meta-analysis reporting an odds ratio of 1.22 per 1 μg/m³ increase in benzene for childhood AML (https://pubmed.ncbi.nlm.nih.gov/41485753/).

How does benzene cause acute myeloid leukemia?

Benzene acts as a myelotoxin, damaging bone marrow. Its mode of action includes hematotoxicity, genetic toxicity, oxidative stress, inflammation, immunosuppression, and epigenetic changes (https://pubmed.ncbi.nlm.nih.gov/34069279/). Early key events include observable toxicity in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013/).

What is the latency period between benzene exposure and AML?

The latency period can be years or decades. Occupational studies focus on chronic exposure at 10 ppm or more, with increased risk observed over follow-up periods (https://pubmed.ncbi.nlm.nih.gov/33429013/). The Swiss National Cohort linked exposure to mortality over time (https://pubmed.ncbi.nlm.nih.gov/38727681/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.